TP53 and lung carcinoma: Though previous animal studies [21, 28, 30] and initial human trial [31] indicated that SHK is a relatively safe compound with no adverse side effects, further research is needed to confirm the potential mechanisms of SHK through p53 regulated signaling actions on apoptotic and necrotic inductions in human lung cancer xenograft mouse model for developing more effective strategies for cancer treatment in vivo.